<DOC>
	<DOCNO>NCT00081822</DOCNO>
	<brief_summary>The purpose study determine recommend phase II dose clofarabine administer combination standard dose Ara-C older ( &gt; =60 year age ) patient newly diagnose acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Study Clofarabine &amp; Cytosine Arabinoside Therapy Older Adults With Acute Myeloid Leukemia</brief_title>
	<detailed_description>This phase I/II trial include initial dose escalation clofarabine fix standard dose Ara-C phase I determine 'optimal phase II dose ' . Patients enrol phase I cohorts 3-6 beginning Dose Level I clofarabine ( 30 mg/m2/day , day 2-6 ) . If 0/3 1/6 patient experience dose-limiting toxicity ( DLT ) , clofarabine escalate Dose Level II ( 40mg/m2/day , day 2-6 ) . If &gt; 1/3 ≥2/6 patient experience DLT Dose Level II , Dose Level I declare optimal phase II dose . However , 0/3 1/6 patient experience DLT Dose Level II , Dose Level II declare optimal phase II dose . In event ≥2 patient experience DLT Dose Level I , clofarabine dose reduce Dose Level -I ( 22.5mg/m2/day , day 2-6 ) . Accrual continue cohort 3-6 patient , phase I fashion . If 0/3 1/6 patient experience DLT , Dose Level -I declare 'optimal phase II dose ' . In event ≥2 patient experience DLT Dose Level -I , clofarabine dose reduce Dose Level -II ( 15mg/m2/day , day 2-6 ) . Accrual proceed cohort 3-6 patient . If 0/3 1/6 experience DLT , Dose Level -II declare 'optimal phase II dose ' . In event ≥2 patient experience DLT Dose Level -II , accrual protocol halt . Enrollment proceed optimal phase II dose Simon 2-stage design determine CR rate treatment-related mortality initially 16 patient ; CR rate TRM acceptable , enrollment continue approximately 46 patient complete . Induction Therapy ( cycle 1 ) - 7 day cycle Day 1 Aggressive Hydration x12-24hrs , follow Ara-C 100mg/m2/day 24hr IV continuous infusion day 1-7 - PK analysis Ara-C alone Day 1 ( plasma &amp; intracellular ) Day 2 Dexamethasone 10mg IV QD prior clofarabine day 2-6 Clofarabine 2 hour daily infusion day 2-6 - PK analysis Ara-C &amp; clofarabine Day 2 - Bone Marrow Apoptosis analysis ( plasma &amp; intracellular ) Day 3 *Bone Marrow Apoptosis analysis ( plasma &amp; intracellular ) Day 6 *PK analysis Ara-C clofarabine ( plasma ) ( UAB ) Day 8 Initiation prophylactic antibiotic , antifungal &amp; antiviral therapy Day 15 *QOL analysis Day 15-22 Restaging BM Re-Induction appropriate ( see ) Day 16 GM-CSF 250μg/m2 daily ANC &gt; 1,500/μl ( D15 BM aplasia , residual AML ) Day 28-49 Outcome BM , assessment response Re-Induction ( PR ) Post-Remission therapy ( CR ) - QOL analysis 2 week hospital discharge ( approximately Day 42 ) Re-Induction ( cycle 2 appropriate ) ( Partial Remission Induction , day 15-49 ) *5 day cycle Aggressive Hydration x12-24hrs Day 1 Dexamethasone 10mg IV QD day 1-5 Day 1 Clofarabine 2 hour daily infusion day 1-5 Day 1 Ara-C 100mg/m2/day day 1-5 ( begin 4 hour end clofarabine infusion ) Day 7 GM-CSF 250μg/m2 daily may use recovery ANC &gt; 1,500/μl Day 7 Initiation prophylactic antibiotic , antifungal &amp; antiviral therapy Post-Remission Therapy ( cycle 2 &amp; 3 appropriate ) ( Complete Remission Induction ; must ANC &gt; 1,000/μl , platelet &gt; 100/μl ) *5 day cycle Aggressive Hydration x12-24hrs Day 1 Dexamethasone 10mg IV QD day 1-5 Day 1 Clofarabine 2 hour daily infusion day 1-5 Day 1 Ara-C 100mg/m2/day day 1-5 ( begin 4 hour end clofarabine infusion ) Day 7 GM-CSF 250μg/m2 daily may use recovery ANC &gt; 1,500/μl Day 7 Initiation prophylactic antibiotic , antifungal &amp; antiviral therapy Follow-up Monthly x 12 month 3-monthly x 2 year 4-monthly x 1 year 6-monthly x 1 year Annually thereafter</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Have newly diagnose AML ( FAB classification type M0M2 M4M7 WHO classification ) exclude acute promyelocytic leukemia ( APL ) AML follow chromosomal translocation : ( 15 ; 17 ) ( q22 ; q21 ) ; ( 11 ; 17 ) ( q23 ; q21 ) ; ( 11 ; 17 ) ( q13 ; q21 ) ; ( 5 ; 17 ) ( q32 ; q12 ) .. Have great equal 20 % blast bone marrow . Have great equal 20 % cellularity bone marrow . Provide write informed consent . Must 6075 year age diagnosis . Have Karnofsky performance status ≥60 . Women childbearing potential ( &lt; 1 year postmenopausal unless surgically sterilize ) sexually active male must negative urine pregnancy test , agree use effective barrier method birth control ( i.e . latex condom , diaphragm , cervical cap , etc ) avoid pregnancy . Able comply study procedure followup examination . Have adequate organ function indicate follow laboratory value , obtain within 7 day prior registration : Parameter Required Value ( IS unit ) Renal Serum creatinine &lt; 1.1 mg/dL Hepatic Serum bilirubin &lt; 2 x ULN AST ALT ≤5 x ULN ULN = Institutional Upper Limit Normal . Inclusion Laboratory Values Patients preexist myelodysplastic syndrome , antecedent hematologic disorder &gt; 3 month duration , exclude . Those concomitant myelodysplasia/trilineage dysplasia note time diagnosis AML eligible 74 Have secondary AML ( AML follow chemotherapy radiation therapy ) . Have active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment . Have psychiatric disorder ( ) would interfere consent , study participation followup . Are receive chemotherapy corticosteroid ( unless latter administer low dose premedication purpose treatment chronic condition e.g. , rheumatoid arthritis ) . Have receive prior treatment leukemia . Patients receive growth factor , cytokine support , leukapheresis , hydroxyurea , cranial irradiation allow must discontinue treatment least 24 hour prior begin treatment clofarabine . If use , hydroxyurea must discontinue 48 hour prior initiation chemotherapy . Have severe concurrent disease ( severe coronary artery disease ( NYHA class &gt; II ) , significant neurological disorder , uncontrolled diabetes , etc . ) , , judgment investigator , would make patient inappropriate entry study . Have active central nervous system involvement leukemia . Other malignancy within past year , exception basal cell nonmetastatic squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Foran</keyword>
	<keyword>clofarabine</keyword>
	<keyword>cytosine arabinoside</keyword>
	<keyword>acute myeloid leukemia</keyword>
</DOC>